Targeting signaling factors for degradation, an emerging mechanism for TRAF functions

Immunological Reviews

Volumn 266, Issue 1, 2015, Pages 56-71

  Yang, Xiao Dong ^a   Sun, Shao Cong ^b,c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

cIAP; Inflammation; NIK; Non canonical NF B; TRAF2; TRAF3

Indexed keywords

CD137 LIGAND; CYTOKINE; DEUBIQUITINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; INTERFERON REGULATORY FACTOR 5; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; MYELOID DIFFERENTIATION FACTOR 88; OX40 LIGAND; PROTEIN OTUD7B; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR REL; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; NF-KAPPA B KINASE; PROTEIN SERINE THREONINE KINASE;

ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CARCINOGENESIS; CELL MATURATION; CELL SURVIVAL; COLITIS; COMMENSAL; CYTOKINE PRODUCTION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GRAFT VERSUS HOST REACTION; HUMAN; INFLAMMATION; INNATE IMMUNITY; INTRACELLULAR SIGNALING; LYMPHOCYTE FUNCTION; MACROPHAGE; MULTIPLE SCLEROSIS; NATURAL KILLER T CELL; NONHUMAN; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; UBIQUITINATION; ANIMAL; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; NF-KAPPA B; PROTEIN-SERINE-THREONINE KINASES; PROTEOLYSIS; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 2; TNF RECEPTOR-ASSOCIATED FACTOR 3;

EID: 84931068090     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12311     Document Type: Article

References (134)

1. Ha H, Han D, Choi Y. TRAF-mediated TNFR-family signaling. Curr Protoc Immunol 2009;11:11 19D.
2. Xie P. TRAF molecules in cell signaling and in human diseases. J Mol Signal 2013;8:7.
3. Rothe M, Wong SC, Henzel WJ, Goeddel DV. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 1994;78:681-692.
4. Deshaies RJ, Joazeiro CA. RING domain E3 ubiquitin ligases. Annu Rev Biochem 2009;78:399-434.
5. Hacker H, Tseng PH, Karin M. Expanding TRAF function: TRAF3 as a tri-faced immune regulator. Nat Rev Immunol 2011;11:457-468.
6. Dempsey PW, Doyle SE, He JQ, Cheng G. The signaling adapters and pathways activated by TNF superfamily. Cytokine Growth Factor Rev 2003;14:193-209.
7. Liu S, Chen ZJ. Expanding role of ubiquitination in NF-κB signaling. Cell Res 2011;21:6-21.
8. Xiao G, Harhaj EW, Sun SC. NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol Cell 2001;7:401-409.
9. Sun SC. The noncanonical NF-kappaB pathway. Immunol Rev 2012;246:125-140.
10. Hayden MS, Ghosh S. NF-kappaB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 2012;26:203-234.
11. Liao G, Zhang M, Harhaj EW, Sun SC. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem 2004;279:26243-26250.
12. Morrison MD, Reiley W, Zhang M, Sun SC. An atypical tumor necrosis factor (TNF) receptor-associated factor-binding motif of B cell-activating factor belonging to the TNF family (BAFF) receptor mediates induction of the noncanonical NF-kappaB signaling pathway. J Biol Chem 2005;280:10018-10024.
13. He JQ, et al. Rescue of TRAF3-null mice by p100 NF-kappa B deficiency. J Exp Med 2006;203:2413-2418.
14. Jin J, et al. Proinflammatory TLR signalling is regulated by a TRAF2-dependent proteolysis mechanism in macrophages. Nat Commun 2015;6:5930.
15. Lin L, DeMartino GN, Greene WC. Cotranslational biogenesis of NF-kappaB p50 by the 26S proteasome. Cell 1998;92:819-828.
16. Malinin NL, Boldin MP, Kovalenko AV, Wallach D. MAP3K-related kinase involved in NF-κB induction by TNF, CD95 and IL-1. Nature 1997;385:540-544.
17. Sasaki Y, et al. NIK overexpression amplifies, whereas ablation of its TRAF3-binding domain replaces BAFF:BAFF-R-mediated survival signals in B cells. Proc Natl Acad Sci USA 2008;105:10883-10888.
18. Grech AP, Amesbury M, Chan T, Gardam S, Basten A, Brink R. TRAF2 differentially regulates the canonical and noncanonical pathways of NF-kappaB activation in mature B cells. Immunity 2004;21:629-642.
19. Gardam S, Sierro F, Basten A, Mackay F, Brink R. TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor. Immunity 2008;28:391-401.
20. Varfolomeev E, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007;131:669-681.
21. Vince JE, et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007;131:682-693.
22. Vallabhapurapu S, et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol 2008;9:1364-1370.
23. Zarnegar BJ, et al. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adapters cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol 2008;9:1371-1378.
24. Rothe M, Pan M-G, Henzel WJ, Ayres TM, Goeddel DV. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 1995;83:1243-1252.
25. Xie P, Stunz LL, Larison KD, Yang B, Bishop GA. Tumor necrosis factor receptor-associated factor 3 is a critical regulator of B cell homeostasis in secondary lymphoid organs. Immunity 2007;27:253-267.
26. Gardam S, et al. Deletion of cIAP1 and cIAP2 in murine B lymphocytes constitutively activates cell survival pathways and inactivates the germinal center response. Blood 2011;117:4041-4051.
27. Annunziata CM, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007;12:115-130.
28. Keats JJ, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007;12:131-144.
29. Nagel I, et al. Biallelic inactivation of TRAF3 in a subset of B-cell lymphomas with interstitial del(14)(q24.1q32.33). Leukemia 2009;23:2153-2155.
30. Demchenko YN, Glebov OK, Zingone A, Keats JJ, Bergsagel PL, Kuehl WM. Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. Blood 2010;115:3541-3552.
31. Rossi D, et al. Alteration of BIRC3 and multiple other NF-kappaB pathway genes in splenic marginal zone lymphoma. Blood 2011;118:4930-4934.
32. Otto C, et al. Genetic lesions of the TRAF3 and MAP3K14 genes in classical Hodgkin lymphoma. Br J Haematol 2012;157:702-708.
33. Bushell KR, et al. Genetic inactivation of TRAF3 in canine and human B-cell lymphoma. Blood 2015;125:999-1005.
34. Lee S, Challa-Malladi M, Bratton SB, Wright CW. nuclear factor-kappaB-inducing kinase (NIK) contains an amino-terminal inhibitor of apoptosis (IAP)-binding motif (IBM) that potentiates NIK degradation by cellular IAP1 (c-IAP1). J Biol Chem 2014;289:30680-30689.
35. Zheng C, Kabaleeswaran V, Wang Y, Cheng G, Wu H. Crystal structures of the TRAF2: cIAP2 and the TRAF1: TRAF2: cIAP2 complexes: affinity, specificity, and regulation. Mol Cell 2010;38:101-113.
36. McPherson AJ, Snell LM, Mak TW, Watts TH. Opposing roles for TRAF1 in the alternative versus classical NF-kappaB pathway in T cells. J Biol Chem 2012;287:23010-23019.
37. Lavorgna A, De Filippi R, Formisano S, Leonardi A. TNF receptor-associated factor 1 is a positive regulator of the NF-kappaB alternative pathway. Mol Immunol 2009;46:3278-3282.
38. Silke J, Vucic D. IAP family of cell death and signaling regulators. Methods Enzymol 2014;545:35-65.
39. Vandenabeele P, Bertrand MJ. The role of the IAP E3 ubiquitin ligases in regulating pattern-recognition receptor signalling. Nat Rev Immunol 2012;12:833-844.
40. Brown KD, Hostager BS, Bishop GA. Differential signaling and tumor necrosis factor receptor-associated factor (TRAF) degradation mediated by CD40 and the Epstein-Barr virus oncoprotein latent membrane protein 1 (LMP1). J Exp Med 2001;193:943-954.
41. Bishop GA. The multifaceted roles of TRAFs in the regulation of B-cell function. Nat Rev Immunol 2004;4:775-786.
42. Hu H, et al. OTUD7B controls non-canonical NF-kappaB activation through deubiquitination of TRAF3. Nature 2013;494:371-374.
43. Evans PC, Taylor ER, Coadwell J, Heyninck K, Beyaert R, Kilshaw PJ. Isolation and characterization of two novel A20-like proteins. Biochem J 2001;357:617-623.
44. Enesa K, et al. NF-kappaB suppression by the deubiquitinating enzyme Cezanne: a novel negative feedback loop in pro-inflammatory signaling. J Biol Chem 2008;283:7036-7045.
45. le Luong A, et al. Cezanne regulates inflammatory responses to hypoxia in endothelial cells by targeting TRAF6 for deubiquitination. Circ Res 2013;112:1583-1591.
46. Bremm A, Freund SM, Komander D. Lys11-linked ubiquitin chains adopt compact conformations and are preferentially hydrolyzed by the deubiquitinase Cezanne. Nat Struct Mol Biol 2010;17:939-947.
47. Harhaj EW, Dixit VM. Regulation of NF-kappaB by deubiquitinases. Immunol Rev 2012;246:107-124.
48. Evans PC, et al. A novel type of deubiquitinating enzyme. J Biol Chem 2003;278:23180-23186.
49. Hostager BS, Haxhinasto SA, Rowland SL, Bishop GA. Tumor necrosis factor receptor-associated factor 2 (TRAF2)-deficient B lymphocytes reveal novel roles for TRAF2 in CD40 signaling. J Biol Chem 2003;278:45382-45390.
50. Fotin-Mleczek M, et al. Tumor necrosis factor receptor-associated factor (TRAF) 1 regulates CD40-induced TRAF2-mediated NF-kappaB activation. J Biol Chem 2004;279:677-685.
51. Ganeff C, et al. Induction of the alternative NF-kappaB pathway by lymphotoxin alphabeta (LTalphabeta) relies on internalization of LTbeta receptor. Mol Cell Biol 2011;31:4319-4334.
52. de Jong SJ, Albrecht JC, Giehler F, Kieser A, Sticht H, Biesinger B. Noncanonical NF-kappaB activation by the oncoprotein Tio occurs through a nonconserved TRAF3-binding motif. Sci Signal 2013;6:ra27.
53. Heinemann S, Biesinger B, Fleckenstein B, Albrecht JC. NFkappaB signaling is induced by the oncoprotein Tio through direct interaction with TRAF6. J Biol Chem 2006;281:8565-8572.
54. Saitoh T, Nakayama M, Nakano H, Yagita H, Yamamoto N, Yamaoka S. TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J Biol Chem 2003;278:36005-36012.
55. Wicovsky A, et al. TNF-like weak inducer of apoptosis inhibits proinflammatory TNF receptor-1 signaling. Cell Death Differ 2009;16:1445-1459.
56. Vince JE, et al. TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha. J Cell Biol 2008;182:171-184.
57. Sanjo H, Zajonc DM, Braden R, Norris PS, Ware CF. Allosteric regulation of the ubiquitin:NIK and ubiquitin:TRAF3 E3 ligases by the lymphotoxin-beta receptor. J Biol Chem 2010;285:17148-17155.
58. Claudio E, Brown K, Park S, Wang H, Siebenlist U. BAFF-induced NEMO-independent processing of NF-kappaB2 in maturing B cells. Nat Immunol 2002;3:958-965.
59. Dejardin E. The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem Pharmacol 2006;72:1161-1179.
60. Chan TD, Gardam S, Gatto D, Turner VM, Silke J, Brink R. In vivo control of B-cell survival and antigen-specific B-cell responses. Immunol Rev 2010;237:90-103.
61. Staudt LM. Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol 2010;2:a000109.
62. Yi Z, Lin WW, Stunz LL, Bishop GA. Roles for TNF-receptor associated factor 3 (TRAF3) in lymphocyte functions. Cytokine Growth Factor Rev 2014;25:147-156.
63. Tucker E, et al. A novel mutation in the Nfkb2 gene generates an NF-kappa B2 "super repressor". J Immunol 2007;179:7514-7522.
64. Chen K, et al. Germline mutations in NFKB2 implicate the noncanonical NF-kappaB pathway in the pathogenesis of common variable immunodeficiency. Am J Hum Genet 2013;93:812-824.
65. Lee CE, et al. Autosomal-dominant B-cell deficiency with alopecia due to a mutation in NFKB2 that results in nonprocessable p100. Blood 2014;124:2964-2972.
66. Zapata JM, Llobet D, Krajewska M, Lefebvre S, Kress CL, Reed JC. Lymphocyte-specific TRAF3 transgenic mice have enhanced humoral responses and develop plasmacytosis, autoimmunity, inflammation, and cancer. Blood 2009;113:4595-4603.
67. Lin WJ, et al. Crucial role for TNF receptor-associated factor 2 (TRAF2) in regulating NFkappaB2 signaling that contributes to autoimmunity. Proc Natl Acad Sci USA 2011;108:18354-18359.
68. Jin W, Zhou XF, Yu J, Cheng X, Sun SC. Regulation of Th17 cell differentiation and EAE induction by the MAP3K NIK. Blood 2009;113:6603-6610.
69. Murray SE, et al. NF-kappaB-inducing kinase plays an essential T cell-intrinsic role in graft-versus-host disease and lethal autoimmunity in mice. J Clin Invest 2011;121:4775-4786.
70. Rowe AM, Murray SE, Raue HP, Koguchi Y, Slifka MK, Parker DC. A cell-intrinsic requirement for NF-kappaB-inducing kinase in CD4 and CD8 T cell memory. J Immunol 2013;191:3663-3672.
71. Hacker H, Chi L, Rehg JE, Redecke V. NIK prevents the development of hypereosinophilic syndrome-like disease in mice independent of IKKalpha activation. J Immunol 2012;188:4602-4610.
72. Yu J, Zhou X, Nakaya M, Jin W, Cheng X, Sun SC. T cell-intrinsic function of the noncanonical NF-kappaB pathway in the regulation of GM-CSF expression and experimental autoimmune encephalomyelitis. Pathogenesis. J Immunol 2014;193:422-430.
73. Andreakos E, Williams RO, Wales J, Foxwell BM, Feldmann M. Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant. Proc Natl Acad Sci USA 2006;103:14459-14464.
74. + regulatory T cells. Autoimmunity 2006;39:445-453.
75. Lind EF, et al. Dendritic cells require the NF-kappaB2 pathway for cross-presentation of soluble antigens. J Immunol 2008;181:354-363.
76. Hofmann J, Mair F, Greter M, Schmidt-Supprian M, Becher B. NIK signaling in dendritic cells but not in T cells is required for the development of effector T cells and cell-mediated immune responses. J Exp Med 2011;208:1917-1929.
77. Olashaw NE. Inducible activation of RelB in fibroblasts. J Biol Chem 1996;271:30307-30310.
78. O'Sullivan BJ, Thomas R. CD40 ligation conditions dendritic cell antigen-presenting function through sustained activation of NF-kappaB. J Immunol 2002;168:5491-5498.
79. Schjerven H, Tran TN, Brandtzaeg P, Johansen FE. De novo synthesized RelB mediates TNF-induced up-regulation of the human polymeric Ig receptor. J Immunol 2004;173:1849-1857.
80. Authier H, et al. IKK phosphorylates RelB to modulate its promoter specificity and promote fibroblast migration downstream of TNF receptors. Proc Natl Acad Sci USA 2014;111:14794-14799.
81. Basak S, et al. A fourth IkappaB protein within the NF-kappaB signaling module. Cell 2007;128:369-381.
82. Zarnegar B, Yamazaki S, He JQ, Cheng G. Control of canonical NF-kappaB activation through the NIK-IKK complex pathway. Proc Natl Acad Sci USA 2008;105:3503-3508.
83. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 2009;9:271-285.
84. Watts TH. Tnf/Tnfr family members in costimulation of T cell responses. Annu Rev Immunol 2005;23:23-68.
85. Michel M, Wilhelmi I, Schultz AS, Preussner M, Heyd F. Activation-induced tumor necrosis factor receptor-associated factor 3 (Traf3) alternative splicing controls the noncanonical nuclear factor kappaB pathway and chemokine expression in human T cells. J Biol Chem 2014;289:13651-13660.
86. Yeh WC, et al. Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity 1997;7:715-725.
87. Xu Y, Cheng G, Baltimore D. Targeted disruption of TRAF3 leads to postnatal lethality and defective T-dependent immune responses. Immunity 1996;5:407-415.
88. Xie P, Kraus ZJ, Stunz LL, Liu Y, Bishop GA. TNF receptor-associated factor 3 is required for T cell-mediated immunity and TCR/CD28 signaling. J Immunol 2011;186:143-155.
89. Yi Z, Stunz LL, Bishop GA. TNF receptor associated factor 3 plays a key role in development and function of invariant natural killer T cells. J Exp Med 2013;210:1079-1086.
90. + T cells by CD1-expressing cortical thymocytes. J Exp Med 1995;182:2091-2096.
91. Benlagha K, Kyin T, Beavis A, Teyton L, Bendelac A. A thymic precursor to the NK T cell lineage. Science 2002;296:553-555.
92. Pellicci DG, Hammond KJ, Uldrich AP, Baxter AG, Smyth MJ, Godfrey DI. A natural killer T (NKT) cell developmental pathway involving a thymus-dependent NK1.1(-)CD4(+) CD1d-dependent precursor stage. J Exp Med 2002;195:835-844.
93. + central memory T cells. PLoS ONE 2014;9:e102120.
94. Yi Z, Lin WW, Stunz LL, Bishop GA. The adapter TRAF3 restrains the lineage determination of thymic regulatory T cells by modulating signaling via the receptor for IL-2. Nat Immunol 2014;15:866-874.
95. Burchill MA, et al. Linked T cell receptor and cytokine signaling govern the development of the regulatory T cell repertoire. Immunity 2008;28:112-121.
96. Lio CW, Hsieh CS. A two-step process for thymic regulatory T cell development. Immunity 2008;28:100-111.
97. Chang JH, et al. TRAF3 regulates the effector function of regulatory T cells and humoral immune responses. J Exp Med 2014;211:137-151.
98. Au PY, Yeh WC. Physiological roles and mechanisms of signaling by TRAF2 and TRAF5. Adv Exp Med Biol 2007;597:32-47.
99. Tseng PH, Matsuzawa A, Zhang W, Mino T, Vignali DA, Karin M. Different modes of ubiquitination of the adapter TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines. Nat Immunol 2010;11:70-75.
100. Xiao Y, et al. Peli1 promotes microglia-mediated CNS inflammation by regulating Traf3 degradation. Nat Med 2013;19:595-602.
101. Zhu S, et al. Modulation of experimental autoimmune encephalomyelitis through TRAF3-mediated suppression of interleukin 17 receptor signaling. J Exp Med 2010;207:2647-2662.
102. Ransohoff RM, Brown MA. Innate immunity in the central nervous system. J Clin Invest 2012;122:1164-1171.
103. Lalani AI, et al. Myeloid cell TRAF3 regulates immune responses and inhibits inflammation and tumor development in mice. J Immunol 2015;194:334-348.
104. Shen J, Qiao Y, Ran Z, Wang T, Xu J, Feng J. Intestinal protein expression profile identifies inflammatory bowel disease and predicts relapse. Int J Clin Exp Pathol 2013;6:917-925.
105. Shen J, Qiao YQ, Ran ZH, Wang TR. Up-regulation and pre-activation of TRAF3 and TRAF5 in inflammatory bowel disease. Int J Med Sci 2013;10:156-163.
106. Piao JH, et al. Tumor necrosis factor receptor-associated factor (TRAF) 2 controls homeostasis of the colon to prevent spontaneous development of murine inflammatory bowel disease. J Biol Chem 2011;286:17879-17888.
107. Grumont R, et al. c-Rel regulates interleukin 12 p70 expression in CD8(+) dendritic cells by specifically inducing p35 gene transcription. J Exp Med 2001;194:1021-1032.
108. Krausgruber T, et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol 2011;12:231-238.
109. Sanjabi S, Hoffmann A, Liou HC, Baltimore D, Smale ST. Selective requirement for c-Rel during IL-12 P40 gene induction in macrophages. Proc Natl Acad Sci USA 2000;97:12705-12710.
110. Sanjabi S, et al. A c-Rel subdomain responsible for enhanced DNA-binding affinity and selective gene activation. Genes Dev 2005;19:2138-2151.
111. Takaoka A, et al. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 2005;434:243-249.
112. Moore CR, Liu Y, Shao C, Covey LR, Morse HC 3rd, Xie P. Specific deletion of TRAF3 in B lymphocytes leads to B-lymphoma development in mice. Leukemia 2012;26:1122-1127.
113. Shen RR, et al. TRAF2 is an NF-kappaB-activating oncogene in epithelial cancers. Oncogene 2015;34:209-216.
114. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005;5:953-964.
115. Senovilla L, Aranda F, Galluzzi L, Kroemer G. Impact of myeloid cells on the efficacy of anticancer chemotherapy. Curr Opin Immunol 2014;30:24-31.
116. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 2000;164:6166-6173.
117. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133-146.
118. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23:549-555.
119. Brower V. Macrophages: cancer therapy's double-edged sword. J Natl Cancer Inst 2012;104:649-652.
120. Hagemann T, et al. "Re-educating" tumor-associated macrophages by targeting NF-kappaB. J Exp Med 2008;205:1261-1268.
121. Cook J, Hagemann T. Tumour-associated macrophages and cancer. Curr Opin Pharmacol 2013;13:595-601.
122. Fong CH, et al. An antiinflammatory role for IKKbeta through the inhibition of "classical" macrophage activation. J Exp Med 2008;205:1269-1276.
123. He JQ, Oganesyan G, Saha SK, Zarnegar B, Cheng G. TRAF3 and its biological function. Adv Exp Med Biol 2007;597:48-59.
124. Liu S, et al. MAVS recruits multiple ubiquitin E3 ligases to activate antiviral signaling cascades. eLife 2013;2:e00785.
125. Häcker H, et al. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 2006;439:204-207.
126. Oganesyan G, et al. Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response. Nature 2006;439:208-211.
127. Saha SK, Cheng G. TRAF3: a new regulator of type I interferons. Cell Cycle 2006;5:804-807.
128. Perez de Diego R, et al. Human TRAF3 adapter molecule deficiency leads to impaired Toll-like receptor 3 response and susceptibility to herpes simplex encephalitis. Immunity 2010;33:400-411.
129. Zeng W, Xu M, Liu S, Sun L, Chen ZJ. Key role of Ubc5 and lysine-63 polyubiquitination in viral activation of IRF3. Mol Cell 2009;36:315-325.
130. Jin J, et al. Noncanonical NF-kappaB pathway controls the production of type I interferons in antiviral innate immunity. Immunity 2014;40:342-354.
131. Choudhary S, Boldogh S, Garofalo R, Jamaluddin M, Brasier AR. Respiratory syncytial virus influences NF-kappaB-dependent gene expression through a novel pathway involving MAP3K14/NIK expression and nuclear complex formation with NF-kappaB2. J Virol 2005;79:8948-8959.
132. Liu P, Li K, Garofalo RP, Brasier AR. Respiratory syncytial virus induces RelA release from cytoplasmic 100-kDa NF-kappa B2 complexes via a novel retinoic acid-inducible gene-I{middle dot}NF- kappa B-inducing kinase signaling pathway. J Biol Chem 2008;283:23169-23178.
133. Manches O, Fernandez MV, Plumas J, Chaperot L, Bhardwaj N. Activation of the noncanonical NF-kappaB pathway by HIV controls a dendritic cell immunoregulatory phenotype. Proc Natl Acad Sci USA 2012;109:14122-14127.
134. Ruckle A, Haasbach E, Julkunen I, Planz O, Ehrhardt C, Ludwig S. The NS1 protein of influenza A virus blocks RIG-I-mediated activation of the noncanonical NF-kappaB pathway and p52/RelB-dependent gene expression in lung epithelial cells. J Virol 2012;86:10211-10217.